在生命第二年接种一剂脑膜炎球菌 C 结合疫苗加强针后 12 个月的抗体持久性。
Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life.
机构信息
Centro Superior de Investigación en Salud Pública, Valencia, Spain.
出版信息
Pediatr Infect Dis J. 2010 Aug;29(8):768-70. doi: 10.1097/INF.0b013e3181d9e653.
We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197. Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4-616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5-71.3) when MenC-CRM197 conjugate was used.
我们报告了在 14 至 18 个月大的儿童中进行的为期 12 个月的随访结果，这些儿童接受了结合破伤风类毒素的脑膜炎奈瑟球菌 C 疫苗或 CRM197 的初级和加强疫苗接种。与使用 MenC-CRM197 结合物时血清杀菌抗体几何平均滴度为 45.1（95%CI：28.5-71.3）相比，接受脑膜炎奈瑟球菌 C 组结合破伤风类毒素的儿童的血清保护率（92.8%）和几何平均滴度/血清杀菌活性（410.5；95%CI：273.4-616.3）更高。
Zotero 插件